Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Caffeine and coffee as therapeutics against Alzheimer's disease.

Arendash GW, Cao C.

J Alzheimers Dis. 2010;20 Suppl 1:S117-26. doi: 10.3233/JAD-2010-091249. Review.

PMID:
20182037
2.

Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.

Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, Echeverria V, Potter H.

J Alzheimers Dis. 2009;17(3):661-80. doi: 10.3233/JAD-2009-1087.

PMID:
19581722
3.

Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.

Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J.

Neuroscience. 2006 Nov 3;142(4):941-52. Epub 2006 Aug 28.

PMID:
16938404
4.

Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice.

Cao C, Wang L, Lin X, Mamcarz M, Zhang C, Bai G, Nong J, Sussman S, Arendash G.

J Alzheimers Dis. 2011;25(2):323-35. doi: 10.3233/JAD-2011-110110.

PMID:
21422521
5.

Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.

Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC.

J Alzheimers Dis. 2010;20 Suppl 2:S535-50. doi: 10.3233/JAD-2010-100342.

PMID:
20463404
6.

A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.

Arendash GW, Jensen MT, Salem N Jr, Hussein N, Cracchiolo J, Dickson A, Leighty R, Potter H.

Neuroscience. 2007 Oct 26;149(2):286-302. Epub 2007 Aug 14.

PMID:
17904756
7.

Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.

Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H.

J Alzheimers Dis. 2009;17(3):681-97. doi: 10.3233/JAD-2009-1071. Erratum in: J Alzheimers Dis. 2009 Nov;18(3):727. Wang, Lilly [corrected to Wang, Li]..

8.

GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.

Tian J, Shi J, Zhang L, Yin J, Hu Q, Xu Y, Sheng S, Wang P, Ren Y, Wang R, Wang Y.

Curr Alzheimer Res. 2009 Apr;6(2):118-31.

PMID:
19355846
9.

Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice.

Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT.

J Nutr. 2009 Oct;139(10):1987-93. doi: 10.3945/jn.109.109785. Epub 2009 Aug 5.

10.

Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.

He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, Zhang Y, Xu H, Tempier A, Li X, Li XM.

Neurobiol Aging. 2009 Aug;30(8):1205-16. Epub 2008 Feb 20.

PMID:
18079026
12.

Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice.

Leighty RE, Runfeldt MJ, Berndt DJ, Schleif WS, Cracchiolo JR, Potter H, Arendash GW.

J Neurosci Methods. 2008 Jan 30;167(2):358-66. Epub 2007 Aug 19.

PMID:
17904642
13.

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW.

J Pineal Res. 2009 Aug;47(1):82-96. doi: 10.1111/j.1600-079X.2009.00692.x. Epub 2009 Jun 17.

PMID:
19538338
14.

Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.

Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, Sun X, Zhao L, Yu M, Xu Z, Dong W, Qin Y, Fei G, Zhong C, Xu TL.

Brain. 2010 May;133(Pt 5):1342-51. doi: 10.1093/brain/awq069. Epub 2010 Apr 12.

15.

Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.

Evin G, Zhu A, Holsinger RM, Masters CL, Li QX.

J Neurosci Res. 2003 Nov 1;74(3):386-92.

PMID:
14598315
16.

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF.

Eur J Neurosci. 2006 Jan;23(1):251-60.

PMID:
16420434
17.

Chronic psychosocial stress exacerbates impairment of cognition and long-term potentiation in beta-amyloid rat model of Alzheimer's disease.

Srivareerat M, Tran TT, Alzoubi KH, Alkadhi KA.

Biol Psychiatry. 2009 Jun 1;65(11):918-26. doi: 10.1016/j.biopsych.2008.08.021. Epub 2008 Oct 11.

PMID:
18849021
18.

Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.

Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O.

Ann Neurol. 2004 Jun;55(6):801-14.

PMID:
15174014
19.

Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro.

Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu P.

Neurosci Lett. 2009 Mar 13;452(2):90-5. doi: 10.1016/j.neulet.2009.01.013. Epub 2009 Jan 13.

PMID:
19154776
20.

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R.

J Mol Neurosci. 2003;20(3):349-56. Review.

PMID:
14501019
Items per page

Supplemental Content

Write to the Help Desk